Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Fibrin Patch: Phase I data

In an open-label, Israeli Phase I trial in 10 patients undergoing elective

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE